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Abstract
It is unknown whether patients with LTBI at high vs. low risk of developing active TB are cur-
rently adequately identified and treated in the US. In this study our objective was 1) To retro-
spectively apply the online calculator (tstin3d.com) to determine the probability of having
LTBI and assign cumulative risk of progression. 2) Measure treatment outcomes in subjects
with Low: 0-<10%, Intermediate: 10-<50% and High: 50–100% cumulative risk. We per-
formed medical record review of tuberculin skin test and/or Interferon-γ release assay
(IGRAs) positive patients with LTBI seen from 2010–2015. Of 125 subjects included, 51
(41%), 46 (37%) and 28 (22%) subjects were in Low, Intermediate and High risk groups
respectively. Tstin3d.com was useful in determining the probability of LTBI in tuberculin skin
test positive US-born subjects. Overall treatment completion rate was 61% in 114 subjects
with complete treatment information and similar completion rates were seen in the three
groups (Low-60%, Intermediate-63% and High-57%). Provider assessment of important
clinical risk factors was often incomplete. Logistic regression analysis showed no associa-
tion of assessment of important risk factors with treatment completion. The major limitations
of the calculator are the lack of an updated data on country-specific prevalence of TB dis-
ease as the global burden of TB continues to decrease as well as falsely high positive pre-
dictive values that due to “transiently” positive IGRA results in subjects from countries with
low prevalence. Nonetheless, our findings suggest that tstin3d.com could be utilized in the
US setting for improving providing awareness of risk stratification of patients with LTBI for
short course treatment regimens based on risk.
Introduction
Treatment of Latent Tuberculosis Infection (LTBI) decreases the risk of progression to active
TB by 60–90% [1]and both the CDC and WHO recommend treatment of subjects with LTBI
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[2] in low burden TB countries like the US where the overall active TB rates are<10/1000 pop-
ulation. However, TB incidence in the US has plateaued at 3.0 cases per 100,000 persons from
2013–2015 [3]. The exact reasons for this are unclear but poor rates of LTBI treatment comple-
tion (i.e. 50% or less on average) [4] is a likely contributing factor. In part, poor completion
rates are due to prolonged treatment required in subjects with LTBI with Isoniazid (INH) for
6–9 months or 4 months of Rifampin. Recently, a 3 month directly observed regimen of weekly
INH and Rifapentine (3HP) is approved by the CDC, has shown equivalent efficacy. This regi-
men is only recommended in select clinical high risk groups [5]. Although certain clinical risk
factors such as being infected with HIV, diabetes, recent contact with an active TB patient or
receiving immune modulatory drugs like TNF-α blocker therapy are well known to increase
the risk of developing TB disease, data are lacking on the frequency with which a comprehen-
sive assessment of all clinical risk factors is performed in subjects with LTBI by health care pro-
viders. Provider awareness of a subject being at high risk of progression to active TB could
facilitate treatment completion using shorter regimens in those at high risk. www.tstin3d.com
is a free online calculator that combines TST and/or IGRA screening results with other clini-
cally pertinent information, to estimate the positive predictive value (PPV) of TB infection as
well as individual’s annual and cumulative risk of progression to active TB. The calculator has
never been externally validated as a study looking at progression of LTBI to active TB will be
unethical in the US and current CDC guidelines recommend offering treatment to all subjects
with LTBI.
Such assessments not only allow the identification of patients that are at high risk of pro-
gression [6] but could be used to select shorter, supervised regimens to ensure treatment com-
pletion in that group. Therefore, to assess utility of the calculator in a clinical setting, we used
it to perform a retrospective systematic quantification of risk, assessed provider risk awareness
and compared treatment completion rates in subjects at “Low”, “Intermediate” and “High”
risk of LTBI reactivation.
Study population and methods
Data were collected retrospectively on 125 adult patients (�18 years and�80 years) with LTBI
(screened using ICD9/10 LTBI diagnosis codes) that were seen in the Saint Louis University
Infectious Diseases outpatient clinic between January 1, 2010 and December 31st, 2015.
Patients with a positive TST and/or IGRA result without active TB or prior history of treat-
ment for LTBI or active TB were included. Variables (listed in Supplemental Methods)
required by tstin3d.com to estimate an individual’s annual and cumulative risk of LTBI reacti-
vation were obtained from patient electronic medical records. Data on race was collected only
for US born individuals. Information about type and duration of antibiotic therapy, last
known documented follow-up, frequency with which healthcare providers assessed the risk
factors affecting risk of progression to active TB and reasons for discontinuation were
obtained. The study was approved by the St Louis University Institutional Review Board
which waived the requirement for Informed consent as de-identified patient information was
used.
Variables generated by the calculator
The calculator generated positive predictive value (PPV), annual and cumulative risks (up to
age 80 years) of progression to active TB disease (details in Supplemental Methods). The cal-
culator was developed from comprehensive data obtained from systematic reviews and meta-
analysis [7, 8] and encompasses all the well-known risk factors predisposing to TB disease. It
derives the baseline annual risk of TB disease from a large cohort (1,216,425 subjects) of
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healthy TST-positive US military recruits followed up for 4 years to study development of TB
disease [9]. The cumulative risk refers to the annual risk of TB reactivation multiplied by the
number of years before the patient reaches an age of 80 years.
Analysis
Concordance between TST and IGRA in subjects that received both tests was analyzed by
McNemar’s test of corrected proportions. Descriptive statistics were analyzed to determine the
characteristics of subjects with a PPV of greater than 50% along with characteristics and treat-
ment outcomes of patients in Low (<10%), Intermediate (10% to<50%), and High (50%-
100%) cumulative risk categories. Fisher’s exact test was used to determine the association
between the types of drug regimen with treatment completion rates. Logistic regression analy-
sis was performed to examine the association between provider assessment of an individual
clinical risk factor and the patient’s likelihood of completing the treatment. All risk factor
assessments were done per available documentation in patient’s electronic medical record,
either from the Infectious Diseases clinic provider notes or notes entered by any healthcare
provider. If data on a specific medical risk factor was not available, it was decided to not
include it for cumulative risk assessment. If documentation of BCG status was not available in
the medical record, we used the patient’s country of origin to determine BCG vaccination pol-
icy per the BCG world atlas (http://www.bcgatlas.org/index.php). All statistical analyses were
conducted using SAS 9.4 (SAS Institute, Cary, NC), two-sided with a significance level of 0.05.
Results
Characteristics of the study subjects
Table 1 shows the baseline demographic information for the study subjects. The median age
was 49 years with 43.31% female. Of the 125 patients included, 94 were from the US and US
territories, 30 were non-US born and 1 unknown. Among US-born, most were Caucasian
(52%) or African American (43%). The mean age at immigration for non-US born subjects
was 28.5 years. TST data were available on 69 and IGRA data on 91 subjects. Of all 35 TST pos-
itive subjects with IGRA results available, 19 were IGRA positive, 13 were negative and 1 inde-
terminate. Only 2 subjects with positive IGRA had a negative TST result (Fig 1). There was
significant discordance between the two tests (p = 0.0045, McNemar’s test) in subjects who
underwent both TST and IGRA for diagnosis. 56 had a positive IGRA (either a Quantiferon-
TB Gold or T-spot TB) and 34 had a positive TST as their only test.
Positive predictive value of TST
Foreign born subjects who were TST positive/IGRA unavailable were from high or intermedi-
ate TB burden countries and consequently had a PPV value of 50% or greater for being TST
positive. Therefore, tstin3d.com was primarily useful for calculating the PPV in 22 US-born
subjects with positive TST with indeterminate or unavailable IGRA. The calculator assigns
higher PPV to the Non-Hispanic Black/African-Americans with a positive TST and conse-
quently higher number of Non-Hispanic Black/African-American subjects were in the>50%
PPV group compared to those with PPV<50%.
Risk of reactivation
The overall distribution of risk factors in the study patients comparing US born with immi-
grants is shown in Fig 2. HIV, diabetes, history of smoking, taking a TNF-α inhibitor and on
transplant immunosuppression were more common in US born subjects compared to
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immigrants. The median cumulative risk in TST positive/IGRA negative individuals was 19%,
suggesting that they were not in the high-risk group. AIDS patients had the highest annual
(>10%) and cumulative (>50%) risk. A larger proportion of African Americans (20% and
43%) were in the highest annual and cumulative risk category compared to Caucasians (2%
and 16%) and this could be partly due to higher risk assigned to African Americans compared
to age and sex matched Caucasians. However, the risk increase was primarily because of the
significantly increased prevalence of HIV/AIDS noted in African Americans (15/42, 37.5%)
Table 1. Characteristics of patients with latent tuberculosis infection.
Patient Characteristics Number (min to max)
Median Age (years) 49, Range:22–80
Median age at immigration to USA (years) 28.5 (3–45)
Height (cm) 170.2 (147.3–195.6)
Weight (kg) 82.5 (47.3–175.1)
BMI (kg/m^2) 29.15 (18.7–55.39)
Patient demographics Number (%)
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compared to Caucasians (4/49, 8.2%) (p = 0.001 Fisher exact test). Table 2 shows characteris-
tics of all the patients in the High cumulative risk group.
Risk factors and treatment completion in specific high risk groups
Subjects on TNF-α blockers and LTBI. Data were available for 20 subjects with LTBI on
TNFα blockers. A significantly higher proportion (75%) of subjects on TNFα blockers (TNFα
group) were seen because of recent (< 2 years ago) TST/IGRA conversion, compared to 17.5%
in the control group (76 HIV-negative subjects not on any immunosuppressive therapy,
p = 0.002, Fisher exact test). Subjects on TNFα blockers had less diabetes (6% vs. 26%), smok-
ing >1 pack per day (6% vs. 11%), and renal failure (0% vs. 6%) compared to the control
group. The median cumulative risk of progression to active TB was 17.25% in the TNFα group
(range: 8.6–51.7%) and 5.6% in the control group (range: 0.1–100%). 70% of patients were able
to successfully complete LTBI therapy in the TNFα group.
Subjects with HIV and LTBI. Of the HIV positive population with LTBI, 10 of 20 had
AIDS. The median annual TB-risk amongst HIV, AIDS, and HIV-uninfected patients was 8%
(3–8%), 22% (21–25%), and 0.5% (0–6%). More patients with HIV/AIDS smoked >1 pack-
per-day (30% vs. 13%) compared to HIV-uninfected. Other risk-factors distributed amongst
HIV, AIDS and HIV-uninfected groups were recent TST/IGRA conversion (10%, 30%, and
28%), renal-failure requiring hemodialysis (0%, 10%, and 0%), and diabetes (0%, 10%, 25%).
Fig 1. Showing all subjects included in the study based on whether they had a tuberculin skin test (TST) performed. Those who tested negative on TST or
had no TST results available had to have a positive Interferon Gamma Release Assay (IGRA) i.e. Quantiferon-TB Gold or T-spot TB test to be included in the
study.
https://doi.org/10.1371/journal.pone.0207582.g001
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Most HIV positive patients were prescribed INH (HIV/AIDS: 85%, HIV-uninfected: 39%).
The median treatment-days were longer (274 vs. 117 days) but the rates of treatment comple-
tion were comparable for HIV/AIDS than HIV-uninfected patients (30% vs. 34%). Within the
HIV positive population, there was no difference in CD4+ T cell counts between those that
completed LTBI treatment vs. those that did not. Reasons HIV/AIDS patients stopped therapy
included loss to follow-up (2/6), cost (1/6), hepatitis (1/6), rash (1/6), and clinical contraindica-
tions (1/6).
Treatment completion. Of the 125 subjects included in the analysis, 8 were not offered
any treatment and 3 refused. 59 of 114 (52%) subjects were started on treatment with INH,
24 (21%) on 3HP, 23 (20%) on Rifampin and 8 (7%) on Rifabutin. 69 (61%) subjects completed
the recommended duration of therapy during the study period and none developed active
TB. The completion rates of those treated for LTBI were the best for 3HP and worst for Rifabu-
tin, 75% and 50% subjects respectively (S1 Table). Amongst the documented reasons for inter-
rupted treatment (Fig 3), loss to follow-up accounted for a majority (23 subjects). Other
reasons for stopping that were categorized were: elevated liver enzymes, cost/access, minor
side effects (nausea, vomiting, and diarrhea), rash, drug interactions and clinical decision to
stop. No reasons for stopping were documented in 4 subjects. Importantly, no significant
Fig 2. Showing number of US born (black bars) vs. non-US born (grey bars) subjects with different risk factors for progression to active TB disease in
the overall cohort of patients with latent TB.
https://doi.org/10.1371/journal.pone.0207582.g002
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differences were observed between patients completing therapy in the Low, Intermediate and
High cumulative risk groups (p = 0.54, Chi-square test).
Provider risk assessment. BCG status was documented for only 15 of 32 immigrants.
Less than half of the patients’ initial encounter included documented information about coun-
try of birth, HIV/AIDS status, recent TST/IGRA conversion, young age at infection, recent
TST/IGRA conversion (�2 years ago) and history of cancer (Table 3). Most patients were
assessed for smoking and malnutrition and had received a chest X-ray at or within 3 months
of their Infectious Diseases clinic visit. As shown in Table 4, logistic regression analysis
Table 2. Distribution of medical risk factors for progression to active TB in subjects in the High (50–100% cumulative risk) group.
Risk factor Number Cumulative risk value%
HIV (non-AIDS) 10 100 (Median risk) �
• No comorbidities 0
• Smoker 2
• Recent TST conversion (� 2 years ago) 9
AIDS 10 100 (Median risk) �
• No comorbidities 2
• Fibronodular disease on chest X-ray +Recent TST conversion (� 2 years ago) +renal failure on dialysis 1
• Smoker 4
• Smoker+ Recent TST conversion (� 2 years ago) 2
• Recent TST conversion (� 2 years ago) 6
• Diabetes 1
Recent TST conversion (� 2 years ago) +renal failure on dialysis 1 85.04
Renal failure on dialysis 1 70.3
Recent TST conversion + TNF-α blocker + steroid use 2 51.69, 8.61
Immunosuppression after solid organ transplant 2 100, 87.51
Diabetes+ steroid use + solid organ transplant 1 100
Fibronodular disease on chest X-ray + solid organ transplant 1 69.97
Fibronodular disease on chest X-ray + bone marrow transplant 1 76.15
�All subjects with HIV and/or AIDS had 100% cumulative risk
https://doi.org/10.1371/journal.pone.0207582.t002
Fig 3. Showing the number of patients discontinuing therapy and the primary documented causes by drug group.
https://doi.org/10.1371/journal.pone.0207582.g003
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showed that there was no statistically significant association of risk factor assessment in the
clinic at initial visit with the probability of subjects completing treatment. However, we noted
higher odds of treatment completion in those with documentation of immunosuppression
(HIV/AIDS, steroids, transplant related immunosuppression) as well as of smoking and recent
(� 2 years) TST/IGRA conversion.
Discussion
Our study demonstrates that tstin3d.com can be used to divide subjects with LTBI into Low,
Intermediate and High cumulative risk of developing active TB based on the presence or
absence of a combination of clinical risk factors in the US setting. Current standard of care
practice did not result in higher treatment completion rates for patients in the High-risk
group-an important goal of TB control in low burden countries. Additionally, evaluation of a
Table 3. Subjects with latent tuberculosis who were assessed for the different risk factors by infectious diseases
clinic providers.





QBCG (for immigrants) 15/32 (47%)
QCountryBirth 41/125 (33%)




QRenal Failure 90/125 (72%)
QDM 43/125 (34%)





Table 4. Logistic regression analysis of relating probability of completion of treatment to assessment of selected
individual TB progression risk factors.
Assessed Risk factor� Odds Ratio (Confidence Interval) p value
Renal failure 0.83 (0.35–2.0) 0.67
HIV 1.83 (0.83–4) 0.13
AIDS 1.36 (0.53–3.5) 0.52
Chest X-ray available 0.36 (0.082–1.6) 0.18
Diabetes mellitus 0.89 (0.4–1.9) 0.75
Recent TST conversion (�2 years ago) 0.78 (0.37–1.7) 0.51
On TNF-α blocker 0.72 (0.31–1.7) 0.45
Smoker 1.2 (0.43–3.4) 0.72
On steroids 0.99 (0.39–2.5) 0.97
Transplant immunosuppression 1.56 (0.2–11.4) 0.67
�Young age at TB and Head and Neck cancer are not included as number of subjects assessed were not enough to
include in logistic regression analysis
https://doi.org/10.1371/journal.pone.0207582.t004
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particular risk factor was not associated with improved treatment completion but this could be
because providers often select regimens based on side effect profiles of drugs rather than the
patient’s risk of progression to active TB.
For patients undergoing TST, the calculator (tstin3d.com) facilitates risk interpretation by
using the TST size, PPV of TST and risk of development of disease. A PPV >50% leads to an
increased cumulative risk. There are several limitations of using tstin3d.com, the primary ones
being that it is based on 2004 WHO estimates of country-specific smear positive TB disease
rates and utilizes older data on risk based on TST. Furthermore, the calculator may underesti-
mate the effect of non-tuberculous mycobacterial infections which tend to increase as the prev-
alence of tuberculosis decreases in a country [10]. Additionally, the effects on TST reactions of
BCG and NTM are derived from studies in non-HIV-infected persons, so may not be accurate
in HIV-infected persons. Furthermore, the calculator assigns a default PPV>98% to those
with a positive IGRA. False positive IGRAs remain a concern among specific groups assessed
for LTBI in countries with low prevalence [11]. Similar to others, we found significant discor-
dance between PPD and IGRA positivity in our study [12–14]. We found the calculated PPV
to be most useful in stratifying TST positive US born subjects with unavailable IGRAs as they
are not vaccinated with BCG. Thus, as the global burden of TB decreases, physicians treating
patients with LTBI should consider updated data on country-specific prevalence of TB disease.
Furthermore, they should be mindful of a falsely high PPV that can be assigned by tstin3d.com
due to “transiently” positive IGRA results in subjects from countries with low prevalence e.g.
US healthcare workers.
We noted equivalent treatment completion rates between the different risk groups. Current
CDC guidelines define specific risk groups which should be given high priority for LTBI treat-
ment based on TST size and/or IGRA positivity and clinical risk factors [14]. However, as
shown in our study, these risk factors may not be systematically assessed at all times by the
busy clinician. Although lack of adequate healthcare as well as patient related factors e.g.
homelessness, affect adherence to LTBI treatment [4, 15, 16], specific interventions like shorter
duration of therapy using Rifamycin based regimens and directly observed treatment (DOT)
are well recognized measures to improve treatment adherence [17–19]. This approach also
minimizes the loss to follow up which was the major reason for incomplete treatment in our
cohort. Since this was a retrospective study with a relative small sample size we did not find
any associations of loss to follow-up with specific clinical or social characteristic (e.g. home-
lessness, lack of social support) as reported previously [4].
In agreement with the published literature, we found the highest rates of treatment comple-
tion in the 3HP group. Cytochrome P (CYP) 450 isoenzyme induction by Rifamycin based
regimens remains a concern in subjects with HIV on ARVs. This is especially important as
more than 85% of subjects with HIV/AIDS were prescribed INH and only 30% were able to
complete treatment in our study. Current IDSA guidelines recommend use of 3HP only with
efavirenz (EFV)—or raltegravir (RAL)-based regimens (in combination with either abacavir/
lamivudine [ABC/3TC] or tenofovir disoproxil fumarate/emtricitabine [TDF/FTC]) for treat-
ment of LTBI [5]. A future strategy of temporarily switching HIV positive patients to the
above-mentioned regimens, if clinically feasible, could allow better treatment completion rates
with a 3HP based regimen.
Subjects on TNF-α blockers were referred mainly because of recent TST/IGRA conversion
(within� 2years) which increases their risk of TB reactivation disease. Rifamycin based regi-
mens have recently been shown to be effective with minimal side effects in this group of
patients [20]. Although only 25% of patients on TNF-α blockers were prescribed 3HP, 70%
were able to successfully complete LTBI therapy. This is likely due to close clinic follow-up
that these patients receive for their underlying autoimmune disease.
Risk assessment in latent tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0207582 November 15, 2018 9 / 12
An important limitation of our study is the retrospective nature of data collection from the
electronic health records. If data on a specific medical risk factor was not available, it was
decided to not include it for cumulative risk assessment which could have led to underestima-
tion of actual risk. A second limitation was that subjects already receiving care for co-morbid
conditions at different clinics were referred to our Infectious Diseases clinic, making them
more likely to seek healthcare. These subjects are therefore more likely to have higher rates of
LTBI treatment completion compared to the overall population of subjects with LTBI. Fur-
thermore, as patients were often referred from community and other specialty clinics, ID clinic
providers were often aware of medical comorbidities for e.g. HIV/AIDS, Diabetes, renal failure
on dialysis, and ongoing use of TNF-α blocker use at initial clinic assessment. Therefore, we
probably overestimated the actual frequency with which these risk factors would be assessed
had the provider not been made aware beforehand. Nevertheless, we used relatively strict crite-
ria for inclusion of subjects with previously untreated LTBI in our study and had follow up
data on the majority of our study cohort. Since no numerical risk assessment is performed rou-
tinely by healthcare providers treating patients with LTBI, our study suggests that tstin3d.com
could be a useful tool for improving provider awareness of patients at higher risk of developing
TB disease. Furthermore, prospective design would also allow for testing whether treatment
completion rates can be improved by “risk score targeted” treatment (i.e. selecting a 3HP
based regimen for all subjects at high cumulative risk). The utility of “risk score targeted” treat-
ment as a strategy for decreasing the community burden of TB in the US needs to be validated
in future prospective studies.
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